Tarsus raises $60 million in Series B financing

Tarsus Pharmaceuticals announced the completion of $60 million in Series B financing that will be used to initiate a phase 2b/3 trial of topical ophthalmic TP-03 for the treatment of Demodex blepharitis.

Funds will also be used to “fuel phase 1 and 2 development of other clinical programs,” according to a company press release.

“We founded Tarsus with the mission of bringing to market the first drug for Demodex blepharitis, an important unmet need and one of the largest diseases in anterior segment medicine,” Michael Ackermann, PhD, Tarsus chairman, said in the release.

Included in the financing round, led by Vivo Capital, were Frazier Healthcare Partners, Flying L Partners, Visionary Ventures, Aperture Venture Partners and Horowitz Group.

Tarsus Pharmaceuticals announced the completion of $60 million in Series B financing that will be used to initiate a phase 2b/3 trial of topical ophthalmic TP-03 for the treatment of Demodex blepharitis.

Funds will also be used to “fuel phase 1 and 2 development of other clinical programs,” according to a company press release.

“We founded Tarsus with the mission of bringing to market the first drug for Demodex blepharitis, an important unmet need and one of the largest diseases in anterior segment medicine,” Michael Ackermann, PhD, Tarsus chairman, said in the release.

Included in the financing round, led by Vivo Capital, were Frazier Healthcare Partners, Flying L Partners, Visionary Ventures, Aperture Venture Partners and Horowitz Group.